ETST Buys Meduvo LLC from COO in Related-Party Deal, Reaching 34 States
ETST filed a M&A and Partnerships on elevated volume (3.3× avg).
Summary
ETST acquired Meduvo LLC, a California compounding pharmacy, from COO Mario G. Tabraue in a related-party transaction. The deal expands ETST's network to 34 states and includes plans for sterile compounding certification by 2028.
Key Events · M&A and Partnerships · ETST
-
Acquisition of Meduvo LLC
ETST acquired Meduvo LLC, a California compounding pharmacy, expanding its national footprint to 34 U.S. jurisdictions.
-
Related-Party Transaction
The seller was Mario G. Tabraue, ETST's COO and board member. Independent board members reviewed and approved the transaction as fair and reasonable.
-
Facility Upgrade and Sterile Compounding
ETST is upgrading Meduvo's 2,000-square-foot facility to meet sterility requirements, targeting full regulatory certification for sterile compounding by end of 2028.
-
Strategic Expansion
The acquisition establishes a West Coast operational hub and adds non-sterile compounding capabilities, with potential for high-margin sterile compounding revenue.
Analysis · ETST · Life Sciences
Earth Science Tech acquired Meduvo LLC, a California compounding pharmacy, from its own COO and board member Mario G. Tabraue. Because the transaction involved a related party, it required independent board approval, and the deal expands ETST's dispensing network to 34 U.S. jurisdictions. The company is investing in facility upgrades to pursue sterile compounding certification by end of 2028, which could unlock higher-margin revenue streams.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 29.7% of the 1516 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ETST was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $28.5M. The 52-week trading range was $0.00 to $0.24. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.